Evidence map›Paper›PMID 41883461›Full record

ArticleInternational journal of general medicine2026

Exploring the Mechanisms of the Traditional Herbal Formula Sanshen Dan Against Myocardial Ischemia-Reperfusion Injury: An Integrated Strategy Combining Serum Pharmacochemistry, Network Pharmacology, and Molecular Docking.

Yidi Ma, Xue Fang, Yin Fu, Weitai Kong, Qiang Fu, Rui Qie

Abstract read
In one paragraph

Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yidi Ma *School of Basic Medical Sciences, Heilongjiang University of Traditional Chinese Medicine, Harbin, Heilongjiang, People's Republic of China.
Xue Fang *School of Basic Medical Sciences, Heilongjiang University of Traditional Chinese Medicine, Harbin, Heilongjiang, People's Republic of China.
Yin FuSchool of Basic Medical Sciences, Heilongjiang University of Traditional Chinese Medicine, Harbin, Heilongjiang, People's Republic of China.
Weitai KongSchool of Basic Medical Sciences, Heilongjiang University of Traditional Chinese Medicine, Harbin, Heilongjiang, People's Republic of China.
Qiang FuSchool of Basic Medical Sciences, Heilongjiang University of Traditional Chinese Medicine, Harbin, Heilongjiang, People's Republic of China.
Rui QieThe First Affiliated Hospital, Heilongjiang University of Traditional Chinese Medicine, Harbin, Heilongjiang, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Myocardial ischemia-reperfusion injury (MIRI) is a critical clinical challenge in cardiovascular disease management. Sanshen Dan (SSD), a clinically validated traditional Chinese medicine formula, exerts therapeutic effects on MIRI, but its chemical composition and underlying mechanism remain unclear. This study aimed to systematically elucidate the cardioprotective mechanism of SSD against MIRI using an integrated strategy. Methods: An integrated approach combining serum pharmacochemistry, network pharmacology, machine learning, molecular docking, and molecular dynamics simulation was adopted. 1. Ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) was used to identify blood-absorbed components of SSD after oral administration to Sprague-Dawley rats. 2. Potential targets of these components were predicted via public databases, and overlapping targets with MIRI-related genes were screened to construct a compound-target network, followed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. 3. Three machine learning algorithms (random forest, SVM-RFE, LASSO regression) were applied to identify core therapeutic targets. 4. Molecular docking and 100 ns molecular dynamics simulations were performed to verify the binding affinity and stability of ligand-receptor complexes. Results: A total of 44 blood-absorbed active components of SSD were identified, including flavonoids, saponins, lignans, and phenolic acids. A total of 392 potential therapeutic targets were screened out, which were mainly enriched in apoptosis, HIF-1, TNF-α, and cAMP signaling pathways. Machine learning analysis identified Mmp14, Htr2b, and Ctnnb1 as core targets, and the constructed nomogram model showed excellent predictive performance (AUC = 1, C-index = 1). Molecular docking indicated that 6 core components (eg, Kaempferide-4'-methyl ether-3-glucoside, Licurazide) exhibited strong binding affinity to the core targets, and molecular dynamics simulations confirmed the high stability of these complexes, with mean binding free energy ranging from -20.58 kcal/mol to -34.31 kcal/mol. Conclusion: SSD exerts cardioprotective effects against MIRI via a "multi-component, multi-target, multi-pathway" mode. Its core blood-absorbed components may alleviate MIRI by regulating core targets including Mmp14 and Ctnnb1, and modulating key signaling pathways such as TNF-α and HIF-1. This study provides a scientific basis for the clinical application of SSD and further exploration of traditional Chinese medicine compound formulas.

Indexed as

molecular dockingmulti-target mechanismmyocardial ischemia-reperfusion injurynetwork pharmacologypharmacological basis

Identifiers

PMID41883461
PMCPMC13012634

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.